Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Net Income Loss of -$84.95 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +20.8% in Net Income Loss from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), INOVIO PHARMACEUTICALS, INC.'s Net Income Loss has declined by 248.0%.
- Historical annual values: Fiscal year 2025: -$84.95 million | Fiscal year 2024: -$107.25 million | Fiscal year 2023: -$135.12 million | Fiscal year 2022: -$279.82 million | Fiscal year 2021: -$303.66 million | Fiscal year 2020: -$166.41 million | Fiscal year 2019: -$119.36 million | Fiscal year 2018: -$96.97 million | Fiscal year 2017: -$88.21 million | Fiscal year 2016: -$73.74 million | Fiscal year 2015: -$29.19 million | Fiscal year 2014: -$36.12 million | Fiscal year 2013: -$66.03 million | Fiscal year 2012: -$19.67 million | Fiscal year 2011: -$15.25 million | Fiscal year 2010: -$17.61 million | Fiscal year 2009: -$24.41 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: